Antisense Therapeutics has developed an ASO (ALT1102), which is currently in a phase II trial for treatment of patients with relapsing-remitting multiple sclerosis (RRMS) and DMD. This evidence concerns the gene DMD and relapsing-remitting multiple sclerosis.